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ABSTRAK 
 
Sarkoma sel Langerhans adalah proliferasi neoplastik yang jarang ditemui. Ia 
menunjukan ciri-ciri sitologi yang malignan dan bertindak lebih agresif dari histiositosis 
sel Langerhans. Dalam  laporan ini, kami membentangkan satu kes sarkoma sel 
Langerhans yang melibatkan vetebra torasiks ke lapan pada seorang lelaki berumur 
31 tahun. Walaupun sebelum ini diagnosisnya bergantung pada kehadiran butir 
Birbeck melalui analisis ultrstruktur, dengan kehadiran antibodi monoklonal yang 
sesuai pada tisu paraffin, ekspresi CD1a yang khusus pada neoplasma ini dapat 
ditunjukkan dengan mudah dan seterusnya memberi diagnosis yang spesifik. Dalam 
laporan ini, kami membincangkan ciri-ciri morfologi dan imunohistokimia dalam 
diagnosis sarkoma sel Langerhans tanpa analisis ultrastruktur untuk butir Birbeck. 
Kami juga membincangkan bagaimana immunohistokimia dapat membezakan antara 
sarkoma sel Langerhans dari neoplasma histiositik dan dendritik yang lain. 
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ABSTRACT  
 
Langerhans cell sarcoma is a rare neoplastic proliferation of Langerhans cells that has 
overt malignant cytologic features. It behaves more aggressively than its counterpart, 
Langerhans cell histiocytosis. We present here a case of Langerhans cell sarcoma 
involving the eighth thoracic vertebra in a 31-yr-old man who presented with a two-
month history of back pain. In the past, the diagnosis of Langerhans cell sarcoma 
relied on the demonstration of Birbeck granules. However, with the advent of 
monoclonal antibodies suitable on routinely-fixed tissues, the Langerhans cell 
phenotype can be easily confirmed by CD1a protein expression using 
immunohistochemistry. In this report, we describe the morphological features and the 
immunohistochemical findings of this tumour diagnosed even in the absence of 
Birbeck granules. We also highlighted how immunophenotyping is useful in 
differentiating Langerhans cell sarcoma from other histiocytic and dendritic tumours. 
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INTRODUCTION  
 
The World Health Organization currently 
classifies Langerhans cell derived neo-
plasms as Langerhans cell histiocytosis 
and Langerhans cell sarcoma (Jaffe et al. 
2007). Langerhans cell histiocytosis is a 
proliferating disorder of Langerhans cells, 
whereas Langerhans cell sarcoma is a 
neoplastic proliferation of Langerhans 
cells that have overtly malignant cytologic 
features (Ben-Ezra et al. 1991, Jaffe et 
al. 2007). First diagnosed in 1984 (Wood 
et al. 1984), Langerhans cell sarcoma is 
a very rare disease that can present de 
novo or progress from an antecedent 
Langerhans cell histiocytosis (Lee et al. 
2006). The diagnosis relies on malignant 
cytological features, a typical immuno-
phenotype that consistently shows ex-
pression of CD1a, S-100 protein, and 
Langerin (CD207), and the appearance 
of the typical Birbeck granules demon-
strated by electron microscopy (Ferringer 
et al. 2006, Jaffe et al. 2007). In practice, 
Birbeck granules could be demonstrated 
only in a minority of cases due to the un-
availability of fresh tissues for ultrastruc-
tural analysis. Furthermore, cells may 
lose their ultrastructural characteristics as 
they become less differentiated. In a re-
cent study, Verdijk et al (Verdijk et al. 
2005) found lack of Birbeck granules in 
Langerhans cells to be associated with 
mutation in the Langerin gene. 
Currently, with the availability of antibo-
dies suitable for tissue immunohistoche-
mistry, the identification of the cell of ori-
gin of the different types of tumours can 
easily be performed on formalin-fixed 
paraffin-embedded tissues. In addition, 
the use of antigen retrieval techniques 
has allowed an expanded range of mole-
cules, previously detectable on fresh 
material only, to be studied in these tis-
sues. Immunohistochemistry on paraffin-
embedded tissues now play a major role 
in the diagnosis of Langerhans cell sar-
coma, a diagnosis that has frequently 
been missed in the past. 
In this report, we describe the histo-
morphological and immunohistochemical 
findings of a Langerhans cell sarcoma in 
a 31-year-old man in the absence of ul-
trastructural analysis. 
 
CASE REPORT 
 
The patient was a 31-yr-old male who 
presented with localized back pain at the 
mid-thoracic region for two months. It 
was associated with poor appetite and 
weight loss. The disease was progres-
sive and had caused bilateral lower limb 
weakness and inability to walk. Past 
medical history showed that the patient 
had type 2 diabetes mellitus since he 
was 25 years of age.      
A magnetic resonance imaging (MRI) 
scan revealed a pathological fracture of 
the eighth thoracic vertebra (T8) asso-
ciated with a heterogeneous lesion in-
volving the body and both pedicles, and 
narrowing of the spinal cord canal (Figure 
1A and 1B). A computed tomographic 
(CT) scan guided biopsy of the lesion 
was performed and was sent for histo-
pathological examination.  
Histologically, the biopsy showed frag-
ments of tissue infiltrated by aggregates 
of large cells with overtly malignant fea-
tures. The cells contained abundant 
eosinophilic cytoplasm with markedly 
pleomorphic nuclei, some displaying 
prominent nucleoli (Figure 2). Abnormal 
mitotic figures were frequently seen and 
many multinucleated giant cells were 
present. There were scattered neutro-
phils and eosinophils in the background 
(Figure 2). Immunohistochemical studies 
showed that the malignant cells ex-
pressed CD1a, S100, CD68 and CD4 
(Figure 2). The tumour cells were nega-
tive for CD20, CD3, CD15, CD30, CK, 
MPO, HMB45 and Desmin. The antibod-
ies used and the results obtained are 
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Figure 1: (A) Magnetic resonance imaging (MRI) shows a pathological fracture (arrow) and a lesion in the 
eighth thoracic vertebral body with loss of the normal marrow fat. (B) MRI shows a heterogeneous lesion 
involving the body and both pedicles of the eighth thoracic vertebra with narrowed spinal cord canal (arrow). 
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Figure 2: (A) The biopsy shows infiltration by pleomorphic cells including binucleated and multinucleated 
cells in a background of scattered inflammatory cells. (B) High power view clearly shows the malignant 
features of the cells with abundant eosinophilic cytoplasm. Arrows show two mitotic figures. The neoplastic 
cells are strongly positive for (C) CD1a and (D) CD68. The neoplastic cells are also positive for (E) S100 and 
(F) CD4. 
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Table 1: List of primary primary antibodies used, corresponding cell that express the antigens, antibody 
source, antibody dilution and results of immunostaining. 
 
Antibody Marker Source Dilution Results 
CD1a 
S100 
CD68 
CD4 
CD20 
CD3 
CD15 
CD30 
CK 
MPO 
HMB45 
Desmin 
Langerhans cells 
Dendritic cells 
Pan-macrophages 
T helper cells 
B cells 
T cells 
Granulocytes 
Activated B & T cells 
Epithelial cells 
Myeloid cells 
Melanocytes 
Muscle cells 
Lab Vision 
DAKO 
DAKO 
Lab Vision 
DAKO 
DAKO 
DAKO 
DAKO 
DAKO 
DAKO 
DAKO 
DAKO 
1:30 
1:400 
1:200 
1:25 
1:1000 
1:200 
1:20 
1:20 
1:150 
1:1500 
1:150 
1:150 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
summarized in Table 1. A combination of 
both the morphological and immunohis-
tochemical findings supported the diag-
nosis of Langerhans cell sarcoma. 
The patient underwent anterior and 
posterior instrumentation decompression 
and fusion procedures after which he 
symptomatically improved. He was sub-
sequently planned for radiotherapy. 
 
DISCUSSION 
 
Langerhans cell sarcoma is a rare tu-
mour and most previous reports have 
been in the form of case reports with 
paucity of information from larger series 
of cases (Mardones et al. 2009, 
Takahara et al. 2009). Tani et al (Tani et 
al. 1992) suggested that the diagnosis of 
malignant Langerhans cell neoplasm 
should be made on the basis of the pres-
ence of proliferation of Birbeck granule-
containing tumor cells that have overt 
malignant cytological features such as 
nuclear atypia and frequent mitosis.  
Ultrastructural analysis using electron 
microscope to demonstrate Birbeck 
granules in the cytoplasm of tumour  cells 
however requires fresh tissue that are 
fixed in suitable fixatives such as glu-
taraldehye. Attempts at demonstrating 
Birbeck granules using formalin-fixed 
tissue samples were often unsuccessful 
(Lee et al. 2006, Zhao et al. 2009) due to 
fixation-related tissue ultrastructural 
damage. In the present case, the tissue 
sample was small and was entirely fixed 
in formalin and paraffin embedded, ren-
dering it unsuitable for ultrastructural 
analysis. The diagnosis of Langerhans 
cell neoplasms had been previously 
made without the demonstration of Bir-
beck granules in the tumour cells (Ben-
Ezra et al. 1991, Lee et al. 2006). Ben-
Ezra et al. (1991) could demonstrate Bir-
beck granules in only three of the nine 
cases they reported. 
Fortunately, with the advent of newer 
and better monoclonal antibodies for im-
munohistochemistry, a new marker (i.e., 
CD1a) that is specific for Langerhans 
cells is now available (Favara et al. 1997, 
Krenacs et al. 1993). CD1a represents 
one of the first phases of differentiation of 
the CD1 antigen family. It is expressed 
on cell surfaces of cortical thymocytes 
and Langerhans cells (Krenacs et al. 
1993), but it is not expressed on other 
non-neoplastic macrophages and den-
dritic cells such as interdigitating dendritic 
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cells, follicular dendritic cells and plas-
macytoid dendritic cells (Jaffe et al. 
2007). The narrow specificity of the anti-
body (Krenacs et al. 1993) and the ease 
of the immune staining process renders 
CD1a immunostaining useful as a routine 
procedure for the diagnosis of Langer-
hans cell sarcoma (Nezelof & Basset 
1998). 
In addition to CD1a, the tumour consis-
tently expresses S100 and Langerin 
(CD207). Interestingly, it can cause aber-
rant expression of the T cell marker CD4 
(as shown in the present case) but the 
markers of the B and T cell lineages were 
absent. The immunophenotype of 
Langerhans cell sarcoma is identical to 
that of Langerhans cell histiocytosis 
(Jaffe et al. 2007). Pathologically, the 
differentiation between these two condi-
tions is purely morphological. Neverthe-
less, Langerhans cell sarcoma is associ-
ated with an aggressive clinical course 
and distant metastasis (Ben-Ezra et al. 
1991, Misery et al. 2003, Tani et al. 
1992) and should be considered as a 
separate entity from Langerhans cell 
histiocytosis (Ben-Ezra et al. 1991, Jaffe 
et al.  2007, Tani et al. 1992). 
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